REFERENCES
Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K,
et al. (2020). Treatment with hydroxychloroquine, azithromycin, and
combination in patients hospitalized with COVID-19. Int J Infect Dis
97: 396-403.
Bayry J, Misra N, Latry V, Prost F, Delignat S, Lacroix-Desmazes
S, et al. (2003). Mechanisms of action of intravenous
immunoglobulin in autoimmune and inflammatory diseases. Transfus Clin
Biol 10: 165-169.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC,
et al. (2020). Remdesivir for the Treatment of Covid-19 - Final Report.
N Engl J Med 383: 1813-1826.
Belsky JA, Tullius BP, Lamb MG, Sayegh R, Stanek JR, & Auletta JJ
(2021). COVID-19 in immunocompromised patients: A systematic review of
cancer, hematopoietic cell and solid organ transplant patients. J Infect
82: 329-338.
Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. (2020).
Experimental Treatment with Favipiravir for COVID-19: An Open-Label
Control Study. Engineering (Beijing) 6: 1192-1198.
Calabrese LH, Lenfant T, & Calabrese C (2020). Interferon therapy for
COVID-19 and emerging infections: Prospects and concerns. Cleve Clin J
Med.
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. (2020). A
Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe
Covid-19. N Engl J Med 382: 1787-1799.
Cao W, Liu X, Hong K, Ma Z, Zhang Y, Lin L, et al. (2021).
High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019:
A Multicenter Retrospective Study in China. Front Immunol 12:627844.
Cavalli G, Larcher A, Tomelleri A, Campochiaro C, Della-Torre E, De Luca
G, et al. (2021). Interleukin-1 and interleukin-6 inhibition
compared with standard management in patients with COVID-19 and
hyperinflammation: a cohort study. Lancet Rheumatol 3:e253-e261.
Chatterjee K, Wu CP, Bhardwaj A, & Siuba M (2020). Steroids in
COVID-19: An overview. Cleve Clin J Med.
Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M,
Abbasian L, et al. (2020). A Randomized Clinical Trial of the
Efficacy and Safety of Interferon beta-1a in Treatment of Severe
COVID-19. Antimicrob Agents Chemother 64.
Galeotti C, Kaveri SV, & Bayry J (2020). Intravenous immunoglobulin
immunotherapy for coronavirus disease-19 (COVID-19). Clin Transl
Immunology 9: e1198.
Garibaldi BT, Wang K, Robinson ML, Zeger SL, Bandeen-Roche K, Wang
MC, et al. (2021). Comparison of Time to Clinical Improvement
With vs Without Remdesivir Treatment in Hospitalized Patients With
COVID-19. JAMA Netw Open 4: e213071.
Gharebaghi N, Nejadrahim R, Mousavi SJ, Sadat-Ebrahimi SR, & Hajizadeh
R (2020). The use of intravenous immunoglobulin gamma for the treatment
of severe coronavirus disease 2019: a randomized placebo-controlled
double-blind clinical trial. BMC Infect Dis 20: 786.
Ghazy RM, Almaghraby A, Shaaban R, Kamal A, Beshir H, Moursi A, et
al. (2020). A systematic review and meta-analysis on chloroquine and
hydroxychloroquine as monotherapy or combined with azithromycin in
COVID-19 treatment. Sci Rep 10: 22139.
Group RC (2020). Lopinavir-ritonavir in patients admitted to hospital
with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform
trial. Lancet.
Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al.(2021). Dexamethasone in Hospitalized Patients with Covid-19. N Engl J
Med 384: 693-704.
Investigators R-C, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol
AD, et al. (2021). Interleukin-6 Receptor Antagonists in
Critically Ill Patients with Covid-19. N Engl J Med.
Janiaud P, Axfors C, Schmitt AM, Gloy V, Ebrahimi F, Hepprich M,
et al. (2021). Association of Convalescent Plasma Treatment With
Clinical Outcomes in Patients With COVID-19: A Systematic Review and
Meta-analysis. JAMA 325: 1185-1195.
Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan
V, et al. (2021). Baricitinib plus Remdesivir for Hospitalized
Adults with Covid-19. N Engl J Med 384: 795-807.
Khan FA, Stewart I, Fabbri L, Moss S, Robinson K, Smyth AR, et
al. (2021). Systematic review and meta-analysis of anakinra, sarilumab,
siltuximab and tocilizumab for COVID-19. Thorax.
Lee JS, & Shin EC (2020). The type I interferon response in COVID-19:
implications for treatment. Nat Rev Immunol 20: 585-586.
Li Q, Li W, Jin Y, Xu W, Huang C, Li L, et al. (2020). Efficacy
Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults
Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort
Study. Infect Dis Ther 9: 823-836.
Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et
al. (2020). Convalescent plasma treatment of severe COVID-19: a
propensity score-matched control study. Nat Med 26: 1708-1713.
Lopez-Medina E, Lopez P, Hurtado IC, Davalos DM, Ramirez O, Martinez
E, et al. (2021). Effect of Ivermectin on Time to Resolution of
Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial.
JAMA.
Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, et
al. (2020). The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA
Replication by Targeting the Viral Replication-Transcription Complex in
Cultured Cells. J Virol 95.
Nguyen AA, Habiballah SB, Platt CD, Geha RS, Chou JS, & McDonald DR
(2020). Immunoglobulins in the treatment of COVID-19 infection: Proceed
with caution! Clin Immunol 216: 108459.
Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, & Rajter JJ (2021).
Use of Ivermectin Is Associated With Lower Mortality in Hospitalized
Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen
Study. Chest 159: 85-92.
Solaymani-Dodaran M, Ghanei M, Bagheri M, Qazvini A, Vahedi E, Hassan
Saadat S, et al. (2021). Safety and efficacy of Favipiravir in
moderate to severe SARS-CoV-2 pneumonia. Int Immunopharmacol
95: 107522.
Spagnuolo V, Guffanti M, Galli L, Poli A, Querini PR, Ripa M, et
al. (2020). Viral clearance after early corticosteroid treatment in
patients with moderate or severe covid-19. Sci Rep 10: 21291.
Sutanto H, & Heijman J (2020). Beta-Adrenergic Receptor Stimulation
Modulates the Cellular Proarrhythmic Effects of Chloroquine and
Azithromycin. Front Physiol 11: 587709.
Tang Y, Liu J, Zhang D, Xu Z, Ji J, & Wen C (2020). Cytokine Storm in
COVID-19: The Current Evidence and Treatment Strategies. Front Immunol
11: 1708.
Weisberg E, Parent A, Yang PL, Sattler M, Liu Q, Liu Q, et al.(2020). Repurposing of Kinase Inhibitors for Treatment of COVID-19.
Pharm Res 37: 167.
Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. (2020). The
use of anti-inflammatory drugs in the treatment of people with severe
coronavirus disease 2019 (COVID-19): The Perspectives of clinical
immunologists from China. Clin Immunol 214: 108393.
Zhao H, Mendenhall M, & Deininger MW (2020). Imatinib is not a potent
anti-SARS-CoV-2 drug. Leukemia 34: 3085-3087.
Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X, et al.(2020). Interferon-alpha2b Treatment for COVID-19. Front Immunol
11: 1061.